biOasis makes board appointment
This article was originally published in Scrip
Executive Summary
biOasis Technologies, a Canadian biopharmaceutical company focused on the development and commercialisation of diagnostics and therapeutic delivery systems related to neurological diseases, has elected Dr Reinhard Gabathuler to its scientific advisory board. He was previously chief scientific officer at Angiochem and also served as vice-president, brain research and drug delivery, at BioMarin.